RA Capital Management
VC Fund
Boston, United States
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
- Total investments:
- 572
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $120M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries RA Capital Management invests in
Stages RA Capital Management invests in
Countries RA Capital Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 21 contacts → | |||
Round size
- Series B
- $27M–$151M
- Series C
- $44M–$182M
- Post-IPO Equity
- $35M–$275M
Investment Focus
Industry
- Biotechnology 240 (42%)
- Health Care 153 (27%)
- Therapeutics 97 (17%)
- Pharmaceutical 83 (15%)
- Medical 77 (13%)
Stage
- Series B 102 (18%)
- Series C 65 (11%)
- Post-IPO Equity 63 (11%)
- Series A 61 (11%)
- Funding Round 24 (4%)
Country
- United States 228 (40%)
- United Kingdom 10 (2%)
- Canada 6 (1%)
- China 5 (1%)
- Denmark 4 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Cristina Ghenoiu
Principal
|
Principal | Total investments: 2 | Find email | |
Ajay Yekkirala
VP, Head of Biology
|
VP, Head of Biology | Total investments: 0 | Find email | |
Andrew Levin
Managing Director
|
Managing Director | Total investments: 24 | Find email | |
Barbara Herbst
Deputy Chief Compliance Officer
|
Deputy Chief Compliance Officer | Total investments: 0 | Find email | |
Dan Marks
Venture Senior Associate
|
Venture Senior Associate | Total investments: 1 | Find email | |
| See all 21 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in orderto generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. | $400M / Post-IPO Equity / Sep 14, 2026 | ||
| Solstice Oncology is a clinical stage immuno-oncology company developing a therapeutic that meets cancer at its most vulnerable moment, before surgery, to drive deep pathological response and return patients to lasting health. The company's lead program is targeting colon cancer. | $225M / Series A / Sep 09, 2026 | ||
CaMaRa
|
CaMaRa is a biotechnology company developing new medicines for cardiometabolic conditions, including obesity, diabetes and kidney disease. | Seed / Sep 09, 2026 | |
| Tectora Therapeutics develops oral medicines designed to treat immune-mediated diseases, specifically focusing on immunology and inflammation. The company co-develops its pipeline by utilizing advanced computational drug discovery platforms and preclinical capabilities. Its core value proposition centers on translating clinically validated biologyinto oral small-molecule therapies to address significant unmet patient needs. | $55M / Series A / Sep 09, 2026 | ||
| Korsana Biosciences develops THETA-enabled antibody therapies for neurodegenerative diseases. The company focuses on shuttled monoclonal antibodies that cross the blood-brain barrier to reach central nervous system targets. Its lead program, KRSA-028, is an investigational anti-amyloid beta antibody for Alzheimer’s disease that uses a transferrinreceptor-based shuttle and Fc engineering to improve brain delivery and dosing. Korsana is also advancing additional THETA-based programs for undisclosed neurodegenerative indications. | $380M / Post-IPO Equity / Sep 08, 2026 | ||
| Superluminal Medicines is a generative biological and chemical company accelerating new possibilities in drug discovery and development. Its platform creates candidate-ready compounds with speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. | $65.5M / Series B / Sep 03, 2026 | ||
| Typewriter Therapeutics, Inc. develops mRNA-based gene therapies using a gene writing, or gene writing, platform for precise insertion of therapeutic genes into the genome. The company builds on transposon-based technologies originating from research by Professor Emeritus Haruhiko Fujiwara at the University of Tokyo. Its programs focus on all‑RNA,nonviral gene writing systems that repurpose natural genetic elements to address severe genetic disorders with limited treatment options. Typewriter Therapeutics conducts research and development across its U.S. and Japan operations and collaborates with investors and partners to advance genetic medicine candidates toward the clinic. | $56M / Series A / Sep 02, 2026 | ||
| Robotic microfactories for building net-zero homes 2x faster, 2x cheaper with 10x lower carbon | $40M / Venture - Series Unknown / Aug 31, 2026 | ||
| AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $120M / Series C / Aug 27, 2026 | ||
| Bia Energy is a next-generation energy retailer transforming Latin America’s electricity market. By replacing analog meters with smart metering infrastructure, Bia delivers real-time consumption data and a digital platform that helps businesses and households cut costs, optimize usage, and improve sustainability. Backed by Kaszek, 8VC, GlobalFounders Capital, and Nazca, Bia serves leading companies including Starbucks, Coca-Cola, WeWork, Terpel, Falabella, and IKEA. With rapid growth in Colombia and expansion plans into LatAm, Bia is building the digital backbone of energy retail in the region. | $18.5M / Venture - Series Unknown / Aug 27, 2026 | ||
| See all 572 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does RA Capital Management invest in?
RA Capital Management invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series C stage. Most of the 572 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is RA Capital Management's check size?
RA Capital Management typically joins rounds of $27M–$151M at Series B, $44M–$182M at Series C and $35M–$275M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds RA Capital Management participates in.
How do I contact RA Capital Management?
Public channels for RA Capital Management include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at RA Capital Management?
The team at RA Capital Management includes Cristina Ghenoiu (Principal), Ajay Yekkirala (VP, Head of Biology) and Andrew Levin (Managing Director), among 21 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
